LOX-1 abrogation reduces cardiac hypertrophy and collagen accumulation following chronic ischemia in the mouse

Gene Therapy

Volumn 19, Issue 5, 2012, Pages 522-531

  Lu, J ^a,b   Wang, X ^a   Wang, W ^a   Muniyappa, H ^a   Hu, C ^a   Mitra, S ^a   Long, B ^a   Das, K ^a   Mehta, J L ^a  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^b RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

cardiac remodeling; chronic ischemia; LOX 1

Indexed keywords

ADAM10 ENDOPEPTIDASE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR; ATRIAL NATRIURETIC FACTOR; COLLAGEN TYPE 1; COLLAGEN TYPE 4; DISINTEGRIN; FIBRONECTIN; MATRIX METALLOPROTEINASE 17; MITOGEN ACTIVATED PROTEIN KINASE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTERIAL WALL THICKNESS; ARTERY OCCLUSION; ARTICLE; BRADYCARDIA; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HEART FUNCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HEART STROKE VOLUME; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE HYPERTROPHY; HEMODYNAMICS; IN VITRO STUDY; INFLAMMATION; INTRACELLULAR SIGNALING; ISCHEMIA; LEFT CORONARY ARTERY; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RESPIRATORY DISTRESS; SIGNAL TRANSDUCTION; SURVIVAL; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CARDIOMEGALY; COLLAGEN; CORONARY OCCLUSION; MALE; MICE; MICE, KNOCKOUT; MYOCARDIAL ISCHEMIA; OXIDATIVE STRESS; SCAVENGER RECEPTORS, CLASS E; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

MUS;

EID: 84862123529     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.133     Document Type: Article

References (35)

1. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 2009; 54: 1747-1762.
2. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358: 2148-2159.
3. Sorescu D, Griendling KK. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail 2002; 8: 132-140. (Pubitemid 34669892)
4. Liu X, Gai Y, Liu F, Gao W, Zhang Y, Xu M et al. Trimetazidine inhibits pressure overloadinduced cardiac fibrosis through NADPH oxidase-ROS-CTGF pathway. Cardiovasc Res 2010; 88: 150-158.
5. Doerries C, Grote K, Hilfiker-Kleiner D, Luchtefeld M, Schaefer A, Holland SM et al. Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ Res 2007; 100: 894-903. (Pubitemid 46555695)
6. Cominacini L, Pasini AF, Garbin U, Davoli A, Tosetti ML, Campagnola M et al. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-B through an increased production of intracellular reactive oxygen species. J Biol Chem 2000; 275: 12633-12638. (Pubitemid 30241412)
7. Li D, Saldeen T, Romeo F, Mehta JL. Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells: the potential role of transcription factor NF-kappaB. Circulation 2000; 102: 1970-1976.
8. Iwai-Kanai E, Hasegawa K, Sawamura T, Fujita M, Yanazume T, Toyokuni S et al. Activation of lectin-like oxidized low-density lipoprotein receptor-1 induces apoptosis in cultured neonatal rat cardiac myocytes. Circulation 2001; 104: 2948-2954. (Pubitemid 33139108)
9. Li D, Williams V, Liu L, Chen H, Sawamura T, Romeo F et al. Expression of lectin-like oxidized low-density lipoprotein receptors during ischemia-reperfusion and its role in determination of apoptosis and left ventricular dysfunction. J Am Coll Cardiol 2003; 41: 1048-1055. (Pubitemid 36315552)
10. Hu C, Dandapat A, Chen J, Fujita Y, Inoue N, Kawase Y et al. LOX-1 deletion alters signals of myocardial remodeling immediately after ischemia-reperfusion. Cardiovasc Res 2007; 76: 292-302. (Pubitemid 350198599)
11. Yue H, Li W, Desnoyer R, Karnik SS. Role of nuclear unphosphorylated STAT3 in angiotensin II type 1 receptor-induced cardiac hypertrophy. Cardiovasc Res 2010; 85: 90-99.
12. Oishi Y, Ozono R, Yano Y, Teranishi Y, Akishita M, Horiuchi M et al. Cardioprotective role of AT2 receptor in post-infarction left ventricular remodeling. Hypertension 2003; 41: 814-818. (Pubitemid 36314596)
13. Mehta JL, Chen J, Hermonat PL, Romeo F, Novelli G. Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc Res 2006; 69: 36-45. (Pubitemid 41814809)
14. Li D, Mehta JL. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation 2000; 101: 2889-2895. (Pubitemid 30415877)
15. Chen J, Liu Y, Liu H, Hermonat PL, Mehta JL. Molecular dissection of angiotensin II-activated human LOX-1 promoter. Arterioscler Thromb Vasc Biol 2006; 26: 1163-1168. (Pubitemid 43732128)
16. Li D, Patel AR, Klibanov AL, Kramer CM, Ruiz M, Kang BY et al. Molecular imaging of atherosclerotic plaques targeted to oxidized LDL receptor LOX-1 by SPECT/CT and magnetic resonance. Circ Cardiovasc Imag 2010; 3: 464-472.
17. Kang BY, Mehta JL. Rosuvastatin attenuates Ang II-mediated cardiomyocyte hypertrophy via inhibition of LOX-1. J Cardiovasc Pharmacol Ther 2009; 14: 283-291.
18. Hu C, Dandapat A, Sun L, Khan JA, Liu Y, Hermonat PL et al. Regulation of TGFbeta1-mediated collagen formation by LOX-1: studies based on forced overexpression of TGFbeta1 in wild-type and lox-1 knock-out mouse cardiac fibroblasts. J Biol Chem 2008; 283: 10226-10231.
19. Honjo M, Nakamura K, Yamashiro K, Kiryu J, Tanihara H, McEvoy LM et al. Lectin-like oxidized LDL receptor-1 is a cell-adhesion molecule involved in endotoxin-induced inflammation. Proc Natl Acad Sci 2003; 100: 1274-1279. (Pubitemid 36183992)
20. Ainscough JF, Drinkhill MJ, Sedo A, Turner NA, Brooke DA, Balmforth AJ et al. Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction. Cardiovasc Res 2009; 81: 592-600.
21. Kang BY, Hu C, Ryu S, Biancolella M, Prayaga S, Seung KB et al. Genomics of cardiac remodeling in angiotensin II-treated wild-type and LOX-1-deficient mice. Physiol Genom 2010; 42: 42-54.
22. Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119: 530-537.
23. Hu C, Dandapat A, Chen J, Liu Y, Hermonat PL, Carey RM et al. Over-expression of angiotensin II type 2 receptor (agtr2) reduces atherogenesis and modulates LOX-1, endothelial nitric oxide synthase and heme-oxygenase-1 expression. Atherosclerosis 2008; 199: 288-294.
24. Dandapat A, Hu CP, Chen J, Liu Y, Khan JA, Remeo F et al. Over-expression of angiotensin II type 2 receptor (agtr2) decreases collagen accumulation in atherosclerotic plaque. Biochem Biophys Res Commun 2008; 366: 871-877.
25. Chen K, Chen J, Li D, Zhang X, Mehta JL. Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPAR-gamma ligand pioglitazone. Hypertension 2004; 44: 655-661. (Pubitemid 39435235)
26. Chen K, Li D, Zhang X, Hermonat PL, Mehta JL. Anoxia-reoxygenation stimulates collagen type-I and MMP-1 expression in cardiac fibroblasts: modulation by the PPARgamma ligand pioglitazone. J Cardiovasc Pharmacol 2004; 44: 682-687. (Pubitemid 39587430)
27. Chen K, Chen J, Liu Y, Xie J, Li D, Sawamura T et al. Adhesion molecule expression in fibroblasts: alteration in fibroblast biology after transfection with LOX-1 plasmids. Hypertension 2005; 46: 622-627. (Pubitemid 41376845)
28. Franzke CW, Bruckner-Tuderman L, Blobel CP. Shedding of collagen XVII/BP180 in skin depends on both ADAM10 and ADAM9. J Biol Chem2009; 284: 23386-23396.
29. Schulz B, Pruessmeyer J, Maretzky T, Ludwig A, Blobel CP, Saftig P et al. ADAM10 regulates endothelial permeability and T-cell transmigration by proteolysis of vascular endothelial cadherin. Circ Res 2008; 102: 1192-1201.
30. Weskamp G, Mendelson K, Swendeman S, Le Gall S, Ma Y, Lyman S et al. Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes. Circ Res 2010; 106: 932-940.
31. Chen J, Li D, Schaefer R, Mehta JL. Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan. Atherosclerosis 2006; 184: 295-301. (Pubitemid 43049713)
32. Zhang M, Brewer AC, Schröder K, Santos CX, Grieve DJ, Wang M et al. NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. Proc Natl Acad Sci 2010; 107: 18121-18126.
33. Mehta JL, Sanada N, Hu CP, Chen J, Dandapat A, Sugawara F et al. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res 2007; 100: 1634-1642. (Pubitemid 46897266)
34. Hu C, Dandapat A, Sun L, Marwali MR, Inoue N, Sugawara F et al. Modulation of angiotensin II-mediated hypertension and cardiac remodeling by lectin-like oxidized low-density lipoprotein receptor-1 deletion. Hypertension 2008; 52: 556-562.
35. Ahmed A, Fujisawa T, Nui XL, Ahmad S, Al-Ani B, Chudasama K et al. Angiopoietin-2 confers atheroprotection in apoE-/-mice by inhibiting LDL oxidation via nitric oxide. Circ Res 2009; 104: 1333-1336.